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Since apoptosis appeared to be related to neurodegenerative processes, neuroprotection has been involved in investigation of therapeutic
approaches focused upon pharmacological agents to prevent neuronal programmed cell death. In this regard, erythropoietin (Epo) seems to
play a critical role. The present work was focused on the study of the Epo protective effect upon human neuroblastoma SH-SY5Y cells
subjected to differentiation by staurosporine. Under this condition, profuse neurite outgrowth was accompanied by programmed cell death
(35% of apoptotic cells by Hoechst assay, showing characteristic DNA ladder pattern). A previous treatment with recombinant human Epo
(rHuEpo) increased the expression of the specific receptor for Epo while prevented apoptosis. Simultaneously, morphological changes in
neurite elongation and interconnection induced by staurosporine were blocked by Epo. These Epo effects proved to be associated to the
induction of Bcl-xL at the mRNA and protein levels (RT-PCR and Western blot after immunoprecipitation) and were mediated by activation
of pathways inhibited by wortmannin. In conclusion, the fact that both events induced by staurosporine, cell apoptosis and differentiation,
were prevented in SH-SY5Y cells previously exposed to rHuEpo suggests interrelated signaling pathways triggered by the Epo/EpoR
interaction.
© 2005 Elsevier B.V. All rights reserved.Keywords: Apoptosis; Erythropoietin; SH-SY5Y cell; Neuroprotection; Staurosporine; Bcl-X1. Introduction
The cell death phenomenon, apart from being an important
feature in the development of the nervous system, appears also
to play a role in some neurodegenerative diseases and aging
[1]. The fact that the basic mechanisms underlying these
pathological processes are not clearly understood yet may
explain the lack of targeted effective therapies for the
treatment of these diseases. Therefore, the apoptosis pheno-Abbreviations: Epo, erythropoietin; EpoR, erythropoietin receptor; rHuEpo,
recombinant human erythropoietin; D-MEM, Dulbecco's Modified Eagle
Medium; FBS, fetal bovine serum; PBS, phosphate buffered saline; EtBr,
ethidium bromide; GAPDH, glyceraldehyde-3-phosphate dehydrogenase;
DMSO, dimethylsulfoxide; PI3K, phosphatidylinositol 3-kinase; PKC, protein
kinase C
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doi:10.1016/j.bbamcr.2005.12.011menon has attracted enormous attention during the past few
years mainly to delineate the mechanistic details of the
apoptotic pathways in the nervous system. In this regard,
several studies in vivo and in vitro have shown that
erythropoietin (Epo), a pleiotropic cytokine commonly iden-
tified by its role in bone marrow erythropoiesis, could have a
direct neurotrophic and neuroprotective effect [1,2]. The
possibility that Epo plays a significant biological role in
tissues outside the hematopoietic system has triggered interest
in this hormone as a cytoprotective agent [3–6]. It is now
recognized that cells expressing specific receptors for Epo
(EpoR) are not limited to the erythropoietic lineage, and include
endothelial cells [7] and cells of neuronal origin [8]. Moreover,
Epo and EpoR have been identified in specific areas of the
embryonic, fetal and adult brain of rodents, nonhuman primates
and humans [9–11].
It is known that signal transduction of Epo depends on EpoR
dimerization to activate signaling pathways mediated by
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sites for molecules responsible for subsequent activation of
numerous other signaling pathways. The derived cascade of
intracellular events is crucial for the biological activities
emanating from the Epo/EpoR interaction and it appears certain
that antiapoptotic members of the Bcl-2 family are involved in
cell activation by Epo [12–14].
The detection of Epo synthesis and the expression of EpoR
in the central nervous system was immediately followed by
investigation of the Epo properties as a neuroprotective factor
[2,15,16]. Given the role for Bcl-2 family members in
regulating cell death during nervous system development,
much interest has been given to their involvement in
neuropathological conditions [17].
The human SH-SY5Y neuroblastoma cell line has the
capability of undergoing neuronal maturation [18]. Morphologic
and functional differentiation of these cells can be induced by
staurosporine giving rise to a mature neuronal phenotype
[19,20]. However, staurosporine has been extensively charac-
terized as one of the best inducer of apoptosis in many neuronal
cell types [20–22]. This can be explained by the fact that
staurosporine is a potent and non-specific inhibitor of multiple
protein kinases, including the protein kinase C, which plays an
important role in cellular proliferation, differentiation and cell
survival [23,24].
This study was designed considering the strong relation-
ship of Epo with proliferation, differentiation and survival of
erythroid progenitors [25,26], and the evidences regarding
protection on brain cells by Epo [2,27]. Then, staurosporine-
treated SH-SY5Y cells were used to investigate whether a
complex interplay between cell death and differentiation is
related to the neuroprotective activity of Epo.2. Materials and methods
2.1. Materials
All chemicals used were of analytical grade. Fetal bovine serum (FBS),
Dulbecco's Modified Eagle Medium (D-MEM) and Ham F12 Medium were
obtained from GibcoBRL. Proteinase K, Trizol reagent, specific primers for
EpoR, Bcl-2, Bcl-X and glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
were from Invitrogen Life Technologies. Monoclonal anti-Bcl-xL antibody was
obtained from Chemicon International. Staurosporine, EDTA, Nonidet P40,
wortmannin, L-glutamine, paraformaldehyde, phenylmethylsulfonyl fluoride
(PMSF), aprotinin, leupeptin, pepstatin A, Hoechst 33258 dye and DNAse-free
RNAse were obtained from Sigma-Aldrich. Ready-To-Go T-Primed First-Strand
Kit and chemiluminescent system kit and blots (ECL and Hyperfilm) were
obtained from Amersham Biosciences. Agarose was obtained from Promega,
ethidium bromide (EtBr) from Mallinckrodt, dimethylsulfoxide (DMSO) and
absolute ethyl alcohol from Merck, penicillin-streptomycin from PAA
Laboratories GmbH and Protein A-agarose from BD Transduction Laboratories.
Recombinant human erythropoietin (rHuEpo, Hemax) was supplied by Biosidus
(Argentina).Fig. 1. Programmed cell death induction by staurosporine evaluated by DNA
fragmentation. SH-SY5Y cells were cultured without or in the presence of 10–
100 nM staurosporine and then the corresponding DNA was extracted.
Internucleosomal DNA degradation was detected by electrophoretic analysis
in 2% agarose gels containing EtBr. Bands were observed under UV
transillumination and digitalized.2.2. Cell culture
Human SH-SY5Y neuroblastoma cells (CRL-2266, American Type
Culture Collection ATCC) have been used along this work. Cells were
grown in 25 cm2 culture bottles (Falcon BD) containing 5 ml of 1:1 D-MEM:Ham F12 supplemented with 2 mM L-glutamine, 100 U/ml
penicillin, 100 μg/ml streptomycin and 10% (v/v) heat-inactivated fetal
calf serum. The medium was routinely replaced every 2 days and cultures
maintained at 37 °C in humidified atmosphere containing 95% air-5%
CO2.
2.3. Experimental design
Time-course assays were developed to determine: a) the incubation period
for staurosporine-induced apoptosis and b) the appropriate period of Epo
treatment to prevent apoptosis. Sequential cell treatments were developed in the
presence of wotmannin and addition of rHuEpo previous to the apoptosis
induction with staurosporine.
Staurosporine, rHuEpo and wortmannin were added to complete medium
and adjusted to final concentrations as referred below in text and figures. The
staurosporine vehicle DMSO was added to every control assay.
2.4. Detection of DNA fragmentation by electrophoresis
Approximately 5×106 cells were collected in culture medium, pelleted at
1000×g for 5 min at 4 °C and washed twice with phosphate buffered saline
(PBS). The pellet was homogenized in 500 μl of lysis buffer (0.1 mM NaCl,
25 mM EDTA, 10 mM Tris–HCl pH 8.0, 1% (v/v) Nonidet P40). Digestion in
the presence of 100 μM DNAse-free RNAse A was allowed to proceed during
2 h at 56 °C and then, proteinase K was added at 10 μM final concentration
and each sample incubated for 16 h at 37 °C. Precipitation with half a volume
of 10 M ammonium acetate and 2 volumes of absolute ethyl alcohol was
performed. Electrophoresis of DNA samples were carried out on 2% agarose
gel (w/v), containing 0.5 mg/l EtBr during 90 min at 100 V. Bands were
observed under an UV transilluminator and digitalized with a Kodak DC240
equipment.
2.5. Fluorescent nuclear staining of apoptotic cells
SH-SY5Y cells were cultured on slide covers plated in 35 mm Petri
dishes during 48 h and then, incubated in the presence of staurosporine
at final concentrations ranging from 10 nM to 200 nM during 12 h, or
left untreated. Four plates per experimental condition were simultaneously
run.
Control non-induced and staurosporine-treated cells were fixed with 4%
(v/v) paraformaldehyde in PBS solution for 20 min at 4 °C, exposed to
0.05 g/l Hoechst 33258 dye in PBS for 30 min at room temperature,
Fig. 2. Antiapoptotic effect of Epo demonstrated by DNA fragmentation.
Untreated SH-SY5Y cells were incubated in conventional medium (Lane 1),
with Epo (Lane 2) or wortmannin (Lane 3) alone, induced to apoptosis by
incubation with 25 nM staurosporine for 12 h (Lane 4), treated with 25 U/ml
rHuEpo for 12 h before addition of staurosporine (Lane 5), or subjected to
treatment with 200 nM wortmannin for 2 h, rHuEpo for 12 h and then,
staurosporine during additional 12 h (Lane 6). The electrophoretic result shown
here is representative of three independent experiments.
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(50% glycerol in PBS, v/v).
Fluorescent nuclei with apoptotic characteristics were detected by
microscopy under UV illumination at 365 nm (Eclypse E600 FluorescentFig. 3. Antiapoptotic effect of Epo detected by fluorescence microscopy. (A) Fluores
(a), cells induced to apoptosis by 25 nM staurosporine (d), protected cells treated wi
received a sequential treatment with wortmannin for 2 h, rHuEpo for 12 h and staur
typical characteristics of condensed chromatin detected by microscopy under UV illum
respectively). (B) Positive apoptotic cells counting performed by analyzing 500 cell
cells with respect to the total cell number corresponding to four independent assays. S
controls (a, b and c) and cultures protected by Epo (e).Microscope, Nikon, Japan). The images were photographed by a Nikon Coolpix
5000 equipment and digitalized. Differential cell counting was performed by
analyzing at least 500 cells [26].
2.6. Analysis of mRNA levels by reverse transcriptase-polymerase
chain reaction (RT-PCR)
Total RNA was isolated by means of Trizol reagent. For qualitative
analysis, electrophoresis of RNA was performed in 2% agarose gels (w/v),
stained with EtBr and photographed. The RNA amount and the purity of
extraction were evaluated by measuring absorbance at 260 and 280 nm
[28]. Complementary DNA was prepared by reverse transcription using
Ready-to-Go T-Primed First-Strand Kit starting from a sample of 2 μg of
total RNA.
An aliquot of cDNA was subjected to 30 PCR amplification cycles (94 °C
for 20 s, primer annealing at 62 °C for 30 s, extension at 72 °C for 40 s) with an
initial incubation at 94 °C for 5 min and a final incubation at 60 °C for 7 min for
EpoR and 30 cycles (94 °C for 45 s, 60 °C for 30 s, and 72 °C for 45 s) with
initial incubation at 94 °C for 5 min and final incubation at 72 °C for 10 min for
Bcl-X and Bcl-2. Specific primers were employed for EpoR [29], for Bcl-X and
Bcl-2 [13] and for the internal standard GAPDH [30].
Primers for human EpoR: 5′-TCTGAAGCAGAAGATCTGGCC-3′ and 5′-
GATCATCTGCAGCCTGGTGT-3′.
Primers for human Bcl-2: 5′-AGATGTCCAGCCAGCTGCACCTGAC-3′
and 5′-AGATAGGCACCAGGGTGAGCAAGCT-3′.
Primers for human Bcl-X: 5′-CGGGCATTCAGTGACCTGAC-3′ and 5′-
TCAGGAACCAGCGGTTGAAG-3′.cence photomicrographs after Hoechst 33258 staining of untreated control cells
th rHuEpo for 12 h before being induced with staurosporine (e) and cells which
osporine during 12 h (f). Apoptosis-induced cells show fluorescent nuclei with
ination at 365 nm. No effect of Epo or wortmannin alone was detected (b and c,
s/sample. Each bar represents the percentage value (mean±S.E.M.) of apoptotic
ignificant differences (Pb0.01) of assays induced to apoptosis (d) with respect to
Fig. 4. Regulation of EpoR expression by Epo in SH-SY5Y cells. Cells were
incubated during 12 h in the presence of different rHuEpo concentrations,
ranging from 1 to 25 U/ml. After total RNA extraction, EpoR mRNA was
analyzed by RT-PCR (A) and the protein expression was evaluated by
immunoprecipitation and Western blot (B). (A) PCR fragments were visualized
on 1.5% agarose gels containing EtBr and digitalized. (B) Western blots were
revealed by chemiluminescence using anti-EpoR antibody. (C) The analysis of
EpoR signals, normalized with GAPDH internal standard, are expressed as
arbitrary units of mRNA band density. Results shown in (A) are representative
of four assays similarly run, and densitometric analysis shown in (C) represents
the mean±S.E.M.
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containing EtBr and then digitalized with a Kodak DC240 equipment.
2.7. Immunoprecipitation of cell extracts and Western blotting
Cells were washed with ice-cold PBS solution and lysed with hypotonic
buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 1% Nonidet P-40, 0.1% sodium
dodecylsulfate and 0.5% sodium deoxycholate) containing protease inhibitors (1
mM PMSF, 4 μM leupeptin, 2 μM pepstatin A, 1 μg/ml aprotinin), in a ratio of
200 μl/107 cells. After 30 min incubation on ice, insoluble material was removed
by centrifugation at 15,000×g for 15 min and protein concentration was
measured in supernatants [31].
Two hundred μl of cell extracts were incubated with 3 μg/ml monoclonal
specific antibody (anti-Bcl-X or anti-EpoR antibody) during 1 h at 4 °C. Then,
Protein A-agarose was added and, after overnight incubation at 4 °C in a rotating
shaker, immunoprecipitates were collected by centrifugation at 15,000×g during
15 min and washed twice with the lysis buffer, containing protease inhibitors (1
mM PMSF, 4 μM leupeptin, 2 μM pepstatin A, 1 μg/ml aprotinin) as previously
reported [26].
Immunoprecipitates were boiled for 3 min in the Laemmli buffer [32],
resolved by SDS-polyacrylamide gel electrophoresis (T=8%) and then,
electroblotted onto a Hybond nitrocellulose membrane (transfer buffer: 25
mM Tris, 195 mM glycine, 0.05% SDS, pH 8.3, and 20% (v/v) methanol). Non-
specific binding sites on the membrane were blocked with 5% ECL membrane
blocking agent in Tris-buffered saline (25 mM Tris, 137 mM NaCl, 3 mM KCl,
pH 7.4) containing 0.1% Tween 20 (TBS-Tween) for 1 h at room temperature.
The blots were briefly rinsed using two changes of TBS-Tween buffer, and
washed three times for 10 min each with fresh changes of the washing buffer.
Then, the blots were incubated with the appropriate concentration of the
adequate antibody (anti-Bcl-X or anti-EpoR antibody) during 1 h at 4 °C,
washed again three times for 10 min each with TBS-Tween and probed with a
1:1000 dilution of anti-mouse horseradish peroxidase-conjugated antibody for
1 h at 20 °C. After washing, the blots were incubated with the enhanced
chemiluminescence substrate (ECL kit) and the bands detected by using a
Fujifilm Intelligent Dark Box II (Fuji) equipment coupled to a LAS-1000
digital camera. To visualize the bands the Image Reader LAS-1000 and
LProcess V1.Z2 programs were employed.
2.8. Cell morphology determined by light microscopy
Cells grown at a density of 1×106 cells/ml were treated by the apoptosis
inducer and/or signaling inhibitors as indicated in the legend of the corresponding
figures. After the incubation period, cultures were observed under phase-
contrast, using a 40× objective in an inverted microscope (Axiovert 135, Carl
Zeiss, Germany) and then photographed by using a Nikon Coolpix 5000 digital
camera.Multiple independent images were taken and at least 10 neurites per field
were selected for neurite outgrowth measurement. Finally, means of neurite
length were calculated for each assay. This neurite tracing technique was
implemented in the form of a plugin (NeuronJ) for ImageJ (National Institutes of
Health, Bethesda, MD), the computer-platform independent public domain
image analysis program inspired by NIH-Image [33].
2.9. Statistics
Results are expressed as mean±S.E.M. When corresponding, the non-
parametric Mann–Whitney U-test or the Kruskal–Wallis one-way analysis of
variance test were employed. At least differences with Pb0.05 were considered
the criterion of statistical significance. Correlation between variables was
described by the Pearson r coefficient.
3. Results
3.1. Programmed cell death induction by staurosporine
The ability of staurosporine to act as an effective inducer of
apoptosis upon the SH-SY5Y cells was initially characterizedby analyzing its effect in a range from 10 to 100 nM. Incubation
with staurosporine during a period of 12 h induced clear signs of
cell apoptosis.
One of the apoptosis signs derives from activation of
endogenous endonucleases that attack and degrade preserved
chromatin. This phenomenon was analyzed by means of
electrophoresis in agarose gels. Through this methodology,
the staurosporine-induced cell death was detected by the
appearance of a ladder pattern of DNA degradation (Fig. 1).
This effect was concentration-dependent and no further
changes were observed at staurosporine concentration as high
as 100 nM.
3.2. Antiapoptotic effect of Epo
The effect of Epo on DNA fragmentation induced by
staurosporine was evaluated by incubating cells with 25 U/ml
rHuEpo for 12 h previous to the induction of apoptosis. This
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pattern of DNA fragmentation induced by 25 nM stauros-
porine (Fig. 2). This complete protective effect was less
pronounced due to a shorter Epo exposure. Only a slight
reduction of apoptosis was observed after a pretreatment of 6
h and programmed cell death was not prevented when the
rHuEpo was co-administered with staurosporine. rHuEpo
doses lower than 25 U/ml proved not to be suitable to
completely prevent the effect of 25 nM staurosporine (data
not shown).
Assays in the presence of wortmannin were carried out to
study signaling pathways involved in the antiapoptotic effect of
Epo. Phosphatidylinositol 3-kinase (PI3K), as well as phos-
pholipases A2, C and D, are known as enzymes potentially
inhibited by wortmannin [34]. Cell incubation with 200 nM
wortmannin previously to the addition of rHuEpo inhibited the
protective effect of the hormone (Fig. 2).
Another relevant feature of apoptosis is a specific pattern of
chromatin condensation. Changes in nuclear morphology were
evaluated by fluorescence microscopy, using the Hoechst 33258
dye that specifically binds to DNA. Nuclei in control cells
exhibited diffuse chromatin staining (Fig. 3A.a). However, after
exposure to 25 nM staurosporine for 12 h, cells underwent
typical morphologic changes of apoptosis, such as extreme
nuclear shrinkage and intense bright round bodies of condensed
chromatin (Fig. 3A.d). These characteristic nuclear images of
apoptosis were absent in Epo-pretreated cells (Fig. 3A.e). The
counting of positive apoptotic cells allowed us to describeFig. 5. Expression of members of the Bcl-2 family mediated by Epo. Cells were indu
previous treatment with rHuEpo or sequential previous treatments with wortmannin a
Bcl-X, Bcl-2 and the internal standard GAPDH mRNAwere amplified by RT-PCR. (
and immunoprecipitates analyzed by Western blotting with anti-Bcl-xL antibody an
independent assays. (C) Results of the ratio of Bcl-xL/GAPDH (black bars) and sign
density in bars which indicate mean±S.E.M.different patterns. Whereas the mean value of spontaneous
apoptosis in control cells was low (8.2±0.25%), a significant
increase (Pb0.01) was observed under staurosporine induction
(30.3±0.39%, Pb0.01), and this effect was prevented by the
Epo pretreatment, being the percentage of apoptotic cells
11.1±0.45% (Fig. 3B). On the other hand, a 2-h preincuba-
tion period with wortmannin counteracted the action of Epo
(25.9±0.88%) (Fig. 3A.f and B).
Cell treatments with Epo or wortmannin alone did not induce
apoptotic cell changes in assays of either DNA fragmentation
(Fig. 2: Lanes 2 and 3) or Hoechst nuclear staining (Fig. 3A.b,
A.c and B).
3.3. Regulation of EpoR mRNA by Epo
In order to investigate whether the Epo protective effect
observed on SH-SY5Y cells is mediated by regulation of its
specific receptor expression, cell cultures were developed in the
presence of different rHuEpo concentrations ranging from 1 to
25 U/ml. EpoR mRNA levels and EpoR protein expression
were analyzed by RT-PCR and immunoprecipitation and
Western blot respectively.
Results shown in Fig. 4A demonstrate that EpoR mRNA
levels are dependent on Epo concentration within the range
studied (Pearson coefficient, r = 0.886; P b 0.001). A basal
EpoR mRNA level similar to that observed at 1 U/ml of rHuEpo
was detected in this cell line (data not shown). The analysis of
EpoR mRNA band intensity was expressed as arbitrary units inced or not to apoptosis by staurosporine. In other assays, cells received either a
nd rHuEpo. (A) At the end of the culture periods, total RNAwas extracted, and
B) Cell lysates were immunoprecipitated with anti-Bcl-xL monoclonal antibody,
d chemiluminescent detection. The patterns displayed are representative of four
als of Bcl-xL protein levels (grey bars) were expressed as arbitrary units of band
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GAPDH (Fig. 4C). In addition, increasing EpoR expression at
protein level was observed in cultures stimulated by growing
Epo concentrations (Fig. 4B).
3.4. Expression of factors of the Bcl-2 family mediated by Epo
Taking into consideration that some members of the protein
family Bcl-2 afford resistance to cells facing apoptotic stimuli, it
was interesting to investigate whether the Epo effect was
associated to enhancement of the expression of antiapoptotic
factors of this family. Fig. 5 shows that the regulatory factors
Bcl-xL and Bcl-2 are expressed in SH-SY5Y cells and that the
pretreatment with Epo induces upregulation of Bcl-xL but not of
Bcl-2 mRNA levels (Fig. 5A and C). In agreement, increased
Bcl-xL protein expression was detected by immunoprecipitation
and Western blot in cells which had been protected with Epo
before being treated with staurosporine (Fig. 5B and C). The
upregulation of Bcl-xL expression induced by Epo was
counteracted by cell pretreatment with the inhibitor wortmannin
(Fig. 5).
A 2-h treatment of SH-SY5Y cells with wortmannin alone
had no effect on Bcl-xL expression (data not shown).Fig. 6. Effect of Epo upon staurosporine-induced cell differentiation. (A) Cell growth
following treatments: 25 nM staurosporine for 12 h (d); 25 U/ml rHuEpo for 12 h +
rHuEpo for 12 h+100 nM staurosporine for 12 h (g); 200 nM wortmannin for 2 h+25
(a) and cells treated with Epo (b) or wortmannin (c) alone were also assayed. Magnifi
be seen in (d) and (f). (B) The lengths of neurite outgrowth were measured and resu
Significantly statistical differences (P b 0.05) were found in cultures induced to apop3.5. Effect of Epo on staurosporine-induced cell differentiation
SH-SY5Y cells treated with staurosporine exhibited a
differential neuronal morphology [20–22,35]. Phase contrast
inverted microscopy and photograms were used to monitor
neuritogenesis in cell cultures developed in the presence of
staurosporine with or without Epo-pretreatment for 12 h. The
morphological changes characteristic of cell differentiation
observed after the different experimental protocols are shown
in Fig. 6. The length of neurite outgrowth was measured by an
appropriate software as was indicated in Materials and
methods, and the results, expressed as arbitrary units, are
displayed in Fig. 6B. Neuritogenesis induced by staurosporine
(25 or 100 nM) was observed as an increase in neurite
processes combined with a prominent branching and the
subsequent reduction in cell body size (Fig. 6.d and f with
respect to Fig. 6.a; Pb0.05). Cells pretreated with 25 U/ml Epo
for 12 h failed to differentiate due to 25 nM staurosporine (Fig.
6.e). However, cellular treatment with Epo and higher
staurosporine concentration (100 nM) resulted in some neurite
extension, proving that the inducer effect was partially reverted
(Pb0.05) but could not be completely blocked by the same
Epo dosis (Fig. 6.g). No significant differences were observedwas observed under an inverted microscope and photographed after receiving the
25 nM staurosporine for 12 h (e); 100 nM staurosporine for 12 h (f); 25 U/ml
U/ml rHuEpo for 12 h+25 nM staurosporine for 12 h (h). Untreated control cells
cation 400×. Long neurites emerging and interconnecting cell bodies can clearly
lts (mean ± S.E.M.) of ten independent assays are expressed as arbitrary units.
tosis by staurosporine between cells protected or not by Epo (d vs. e and f vs. g).
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wortmannin alone.
The action of Epo upon cell differentiation was counter-
acted by previous treatment with the inhibitor wortmannin
(Fig. 6h).
4. Discussion
Apoptosis is a mechanism of programmed cell death
involved in the homeostasis of nervous tissues and its
dysregulation has been associated to pathology of neurodegen-
erative diseases. Therefore, neuroprotection has been critically
involved in the investigation of therapeutic approaches that
focuses upon growth factors as pharmacological agents to
prevent neuronal cell apoptosis. In this regard, Epo is considered
to have a major neuroprotective role [2,15,16,27,36]. It is well
known that Epo is related to mechanisms of survival,
proliferation and differentiation of erythroid precursors in
order to increase the circulating erythrocyte mass. However, it
has recently become clear that Epo and its specific receptor
EpoR mediate diverse functions in nonhematopoietic tissues as
well.
Taking into account that staurosporine not only induces
maturation but also triggers the apoptotic phenomenon upon the
human neuroblastoma SH-SY5Y cell line [20], this model was
used to study the response of differentiating cells to the
antiapoptotic effect of Epo. It has been suggested that the
behavior of neurodegenerative tissues is a particularly relevant
field of application of this model, where mechanisms of cell
death can be investigated in a differentiated neuronal cell line
[20]. It is known that apoptosis is induced by various intra- or
extracellular stimuli. In this regard, the effects of staurosporine,
in terms of its ability to induce transient apoptosis during cell
differentiation, might reflect conditions in vivo [20].
In agreement with other authors [20,21], we observed that
staurosporine led to the development of different apoptotic
signs on SH-SY5Y cells, such as DNA fragmentation − made
evident by the typical pattern of electrophoretic ladder − and
nuclear chromatin condensation − revealed by fluorescent
microscopy after Hoechst staining. We also demonstrated that
these signs can be blocked by cell pretreatment with rHuEpo for
at least 12 h before apoptosis was induced by staurosporine and
no protective effect is produced by coadministration of Epo and
the apoptosis inducer.
The finding that rHuEpo exposure increased EpoR expres-
sion at mRNA and protein levels in a dose-dependent fashion
lets us suggest that the effect of rising the level of Epo might be
further amplified in this cell line due to an increase in the
number of the specific receptors.
Given the clear role for Bcl-2 family members in regulating
cell death during nervous system development, much interest
has been focused on their role under neuropathological
conditions. In this context, SH-SY5Y cells overexpressing
antiapoptotic factors of this family were significantly protected
from β-amyloid neurotoxicity [37] and staurosporine induced
apoptosis [20]. On the other hand, the activation of genes of the
bcl-2 family by Epo treatment of retinal ganglion cells has beenreported [38–40]. Based on this knowledge, we hypothesized
that Epo might exert an antiapoptotic effect on SH-SY5Y
neuronal cells through Bcl-2 regulatory factors of apoptosis,
suggesting a mechanism similar to those described in
hematopoietic cells [12–14].
Under the experimental conditions employed, upregulation
of Bcl-xL but not of Bcl-2 was observed following SH-SY5Y
cell activation by Epo. This Epo protective effect was counter-
acted in assays run in the presence of the enzyme inhibitor
wortmannin, with appearance of apoptotic signs and decreased
Bcl-xL mRNA and protein expression. A previous reduction of
Bcl-xL induced by wortmannin before the Epo treatment can be
excluded since a 2-h treatment with the inhibitor alone had no
effect on the expression of the protective factor. Differential
effects of Bcl-2 and Bcl-X in a single cell type with a given
apoptotic stimulus have not been demonstrated conclusively
yet. In erythroid lineages, both antiapoptotic factors are
involved in the regulation of cell survival [12], although Bcl-
xL appears to be the most important in the repression of
apoptosis mediated by Epo [13]. Based on our results, it seems
that Bcl-xL would be also more relevant than Bcl-2 in the
neuroprotective effect of Epo on SH-SY5Y cells induced to
apoptosis by staurosporine. This can be explained by the Bcl-xL
higher efficiency with respect to Bcl-2 in preventing cyto-
chrome c release from mitochondria found by other authors
[20]. Even though Bcl-2 has been considered more related to
regulation of neuronal differentiation [41,42], we did not find
upregulation of this factor due to staurosporine-induced
maturation of SH-SY5Y cells, at least at the drug concentration
and incubation periods used in this study.
In agreement with previous reports [20,21,35], staurospor-
ine proved not only to be an effective inducer of apoptosis but
also a potent inducer of neuritogenesis in SH-SY5Y
neuroblastoma cells. The Epo dosis leading to neuronal
survival, which was associated to Bcl-xL expression, was
also capable of blocking neuritogenesis. Under different
conditions, other authors demonstrated that transfected SH-
SY5Y cells, overexpressing Bcl-xL, acquire enough protection
to resist the severe apoptosis that would be induced by very
high staurosporine doses (1 μM) during long periods, thus
allowing the cells to be induced to differentiation [20]. The
comparison between this and our results supports the
hypothesis that different signaling pathways, other than those
activating bcl-2 genes, may be triggered by Epo, thus affecting
both cell apoptosis and differentiation.
In the present work, cell differentiation produced by low
staurosporine dosis (25 nM) can be blocked by a previous
treatment with 25 U/ml rHuEpo. However, this concentration
was insufficient to overcome the effect of higher staurosporine
levels (100 nM). It seems that Bcl-xL expression induced by
Epo in SH-SY5Y cells increase the threshold for the apoptotic
molecular mechanisms to be activated by staurosporine.
However, it cannot be discarded that Epo counteracts the
inhibitory effect of staurosporine upon PKC, given the role
described for one PKC isoform in mediating Epo-induced
erythroid differentiation of progenitor cells from human bone
marrow [43].
245N. Pregi et al. / Biochimica et Biophysica Acta 1763 (2006) 238–246Our results confirm and extend previous reports on EpoR
expression in human neuronal cells [44] and demonstrate the
EpoR regulation in a ligand dose-dependence. This may explain
further evidence regarding the Epo classic effect of cell
protection upon the human SH-SY5Y cell line. These findings
may be related to mechanisms by which a growth factor
inactivates and/or triggers critical components of the cell-
intrinsic death machinery. The fact that both events induced by
staurosporine, cell apoptosis and differentiation, were prevented
in SH-SY5Y cells previously exposed to rHuEpo suggests
interrelated signaling pathways triggered by the Epo/EpoR
interaction.
Acknowledgements
The authors are grateful to Biosidus (Argentina) for
supplying human recombinant erythropoietin (Hemax) and to
Miss Shirley Wenker, Miss Daiana Vota and Miss María E.
Chamorro for their helpful assistance. This research was
supported by grants from the University of Buenos Aires, the
National Agency for Scientific and Technologic Promotion
(ANPCYT, Argentina) and Alberto J. Roemmers Foundation, as
well as fellowships to Lic. Nicolás Pregi and Dr. Daniela Vittori
from the National Council of Scientific and Technical Research
(CONICET, Argentina). Part of the results included in this work
was presented at the Joint Congress of Biomedical Societies,
Argentina, 2004.
References
[1] P.S. Sastry, K.S. Rao, Apoptosis and the nervous system, J. Neurochem. 74
(2000) 1–20.
[2] M. Buemi, E. Cavallaro, F. Floccari, A. Sturiale, C. Aloisi, M. Trimarchi,
G. Grasso, F. Corica, N. Frisinas, Erythropoietin and the brain: from
neurodevelopment to neuroprotection, Clin. Sci. 103 (2002) 275–282.
[3] M. Sakanaka, T.C. Wen, S. Matsuda, S. Masuda, E. Morishita, M. Nagao,
R. Sasaki, In vivo evidence that erythropoietin protects neurons from
ischemic damage, Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 4635–4640.
[4] M.L. Brines, P. Ghezzi, S. Keenan, D. Agnello, N.C. de Lanerollem, C.
Cerami, L.M. Itri, A. Cerami, Erythropoietin crosses the blood–brain
barrier to protect against experimental brain injury, Proc. Natl. Acad. Sci.
U. S. A. 97 (2000) 10526–10531.
[5] A.L. Siren, M. Fratelli, M. Brines, C. Goemans, S. Casagrande, P.
Lewczuk, S. Keenan, C. Gleiter, C. Pasquali, A. Capobianco, T. Mennini,
R. Heumann, A. Cerami, H. Ehrenreich, P. Ghezzi, Erythropoietin prevents
neuronal apoptosis after cerebral ischemia and metabolic stress, Proc. Natl.
Acad. Sci. U. S. A. 98 (2000) 4044–4049.
[6] K. Maiese, F. Li, Z.Z. Chong, New avenues of exploration for
erythropoietin, JAMA 293 (2005) 90–95.
[7] A. Anagnostou, Z. Liu, M. Steiner, K. Chin, E.S. Lee, N. Kessimian, C.T.
Noguchi, Erythropoietin receptor mRNA expression in human endothelial
cells, Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 3974–3978.
[8] S. Masuda, M. Nagao, K. Takahata, Y. Konishi, F. Gallyas, T. Tabira, R.
Sasaki, Functional erythropoietin receptor of the cells with neural
characteristics. Comparison with receptor properties of erythroid cells,
J. Biol. Chem. 268 (1993) 11208–11216.
[9] A. Nagai, E. Nakagawa, H. Choi, K. Hatori, S. Kobayashi, S.U. Kim,
Erythropoietin and erythropoietin receptors in human CNS neurons,
astrocytes, microglia, and oligodendrocytes grown in culture, J. Neuro-
pathol. Exp. Neurol. 60 (2001) 386–392.
[10] M. Brines, What evidence supports the use of erythropoietin as a novel
neurotherapeutic? Oncology 16 (2002) 79–89 (Suppl.).[11] S. Genc, T.F. Koroglu, K. Genc, Erythropoietin and the nervous system,
Brain Res. 1000 (2004) 19–31.
[12] M. Silva, D. Grillot, A. Benito, C. Richard, G. Núñez, J.L. Fernández-Luna,
Erythropoietin can promote erythroid progenitor survival by repressing
apoptosis through Bcl-xL and Bcl-2, Blood 88 (1996) 1576–1582.
[13] A. Benito, M. Silva, D. Grillot, G. Nuñez, J.L. Fernández-Luna, Apoptosis
induced by erythroid differentiation of human leukemia cell lines is
inhibited by Bcl-xL, Blood 87 (1996) 3837–3843.
[14] Z.Z. Chong, J.Q. Hang, K. Maiese, Hematopoietic factor erythropoietin
fosters neuroprotection through novel signal transduction cascades,
J. Cereb. Blood Flow Metab. 22 (2002) 503–514.
[15] H.H. Marti, M. Bernaudin, E. Petit, C. Bauer, Neuroprotection and
angiogenesis: dual role of erythropoietin in brain ischemia, News Physiol.
Sci. 15 (2000) 225–229.
[16] M. Celik, N. Gökmen, M. Erbayraktar, M. Akhisaroglu, S. Konakc, C.
Ulukus, S. Genc, K. Genc, E. Sagiroglu, A. Cerami, M. Brines,
Erythropoietin prevents motor neuron apoptosis and neurologic disability
in experimental spinal cord ischemic injury, Proc. Natl. Acad. Sci. U. S. A.
99 (2002) 2258–2263.
[17] R.S. Akhtar, J.M. Ness, K.A. Roth, Bcl-2 family regulation of neuronal
development and neurodegeneration, Rev. Biochim. Biophys. Acta 1644
(2004) 189–203.
[18] J.L. Biedler, L. Helson, B.A. Spengler, Morphology and growth,
tumorigenicity and cytogenetics of human neuroblastoma cells in
continuous culture, Cancer Res. 33 (1973) 2643–2652.
[19] A. Jalava, J. Heikkilä, M. Lintunen, K. Åkerman, S. Pahlman,
Staurosporine induces a neuronal phenotype in SH-SY5Y human
neuroblastoma cells that resembles that induced by the phorbol ester 12-
O-tetradecanoyl phorbol-13 acetate (TPA), FEBS Lett. 300 (1992)
114–118.
[20] V. Yuste, I. Sánchez-López, C. Solé, M. Encinas, J. Bayascas, J. Boix, J.
Comella, The prevention of the staurosporine-induced apoptosis by Bcl-
xL, but not by Bcl-2 or caspase inhibitors, allows the extensive
differentiation of human neuroblastoma cells, J. Neurochem. 80 (2002)
126–139.
[21] J.A. Prince, L. Oreland, Staurosporine differentiated human SH-SY5Y
neuroblastoma cultures exhibit transient apoptosis and trophic factor
independence, Brain Res. Bull. 43 (1997) 515–523.
[22] E. López, I. Ferrer, Staurosporine-and H-7-induced cell death in SH-SY5Y
neuroblastoma cells is associated with caspase-2 and caspase-3 activation,
but not with activation of the FAS/FAS-L-caspase-8 signaling pathway,
Mol. Brain Res. 85 (2000) 61–67.
[23] M. Spitaler, D.A. Cantrell, Protein kinase C and beyond, Nat. Rev.,
Immunol. 5 (2004) 785–790.
[24] H. Papp, G. Czifra, E. Bodo, J. Lazar, I. Kovacs, M. Aleksza, I. Juhasz, P.
Acs, S. Sipka, L. Kovacs, P.M. Blumberg, T. Biro, Opposite roles of
protein kinase C isoforms in proliferation, differentiation, apoptosis, and
tumorigenicity of human HaCaT keratinocytes, Cell. Mol. Life Sci. 61
(2004) 1095–1105.
[25] M.J. Koury, The anemia of chronic disease: TNF-α involvement in
erythroid apoptosis, Blood 100 (2002) 373–374.
[26] D. Vittori, N. Pregi, G. Pérez, G. Garbossa, A. Nesse, The distinct
erythropoietin functions that promote cell survival and proliferation are
affected by aluminum exposure through mechanisms involving erythro-
poietin receptor, Biochim. Biophys. Acta 1743 (2005) 29–36.
[27] G. Grasso, A. Sfacteria, A. Cerami, M. Brines, Erythropoietin as a tissue-
protective cytokine in brain injury: what do we know and where do we go?
Neuroscientist 10 (2004) 93–98.
[28] J. Sambrook, D. Russell, Molecular Cloning. A Laboratory Manual, Cold
Spring Harbor Laboratory Press, New York, 2001.
[29] R. Shimizu, N. Komatsu, Y. Miura, Dominant negative effect of a
truncated erythropoietin receptor (EPOR-T) on erythropoietin-induced
erythroid differentiation: possible involvement of EPOR-T in ineffective
erythropoiesis of myelodysplastic syndrome, Exp. Hematol. 27 (1999)
229–233.
[30] M. McKinney, M. Robbins, Chronic atropine administration up-regulates
rat cortical muscarinic m1 receptor mRNA molecules: assessment with the
RT/PCR, Brain Res. Mol. Brain Res. 12 (1992) 39–45.
246 N. Pregi et al. / Biochimica et Biophysica Acta 1763 (2006) 238–246[31] O.H. Lowry, N.J. Roseborough, A.L. Farr, R.L. Randall, Protein
measurements with Folin reagent, J. Biol. Chem. 193 (1951)
267–275.
[32] U.K. Laemmli, Cleavage of structural proteins during the assembly for the
head of bacteriophage T4, Nature 227 (1970) 680–685.
[33] E. Meijering, M. Jacob, J.C. Sarria, P. Steiner, H. Hirling, M.
Unser, Design and validation of a tool for neurite tracing and
analysis in fluorescence microscopy images, Cytometry 58A (2004)
167–176.
[34] M.J. Cross, A. Stewart, M.N. Hodgkin, D.J. Kerr, M.J. Wakelam,
Wortmannin and its structural analogue demethoxyviridin inhibit stimu-
lated phospholipase A2 activity in Swiss 3T3 cells. Wortmannin is not a
specific inhibitor of phosphatidylinositol 3-kinase, J. Biol. Chem. 270
(1995) 25352–25355.
[35] J. Boix, N. Llecha, V.J. Yuste, J.X. Comella, Characterization of the cell
death process induced by staurosporine in human neuroblastoma cell lines,
Neuropharmacology 36 (1997) 811–821.
[36] G. Calapai, M. Marciano, F. Corica, A. Allegra, A. Parisi, N. Frisina, A.
Caputti, M. Buemi, Erythropoietin protects against brain ischemic injury
by inhibition of nitric oxide formation, Eur. J. Pharmacol. 401 (2000)
349–356.
[37] C.M. Luetjens, S. Lankiewicz, N.T. Bui, A.J. Krohn, M. Poppe, J.H.M.
Prehn, Up-regulation of Bcl-xL in response to subtoxic b-amyloid: role in
neuronal resistance against apoptotic and oxidative injury, Neuroscience
102 (2001) 139–150.[38] M.B. Sattler, D. Merkler, K. Maier, C. Stadelmann, H. Ehrenreich, M.
Bahr, R. Diem, Neuroprotective effects and intracellular signaling
pathways of erythropoietin in a rat model of multiple sclerosis, Cell
Death Differ. 11 (Suppl. 2) (2004) S181–S192.
[39] A. Kretz, C.J. Happold, J.K. Marticke, S. Isenmann, Erythropoietin
promotes regeneration of adult CNS neurons via Jak2/Stat3 and PI3K/
AKT pathway activation, Mol. Cell. Neurosci. 29 (2005) 569–579.
[40] M. Yamasaki, H.K. Mishima, H. Yamashita, K. Kashiwagi, K. Murata, A.
Minamoto, T. Inaba, Neuroprotective effects of erythropoietin on
glutamate and nitric oxide toxicity in primary cultured retinal ganglion
cells, Brain Res. 1050 (2005) 15–26.
[41] K. Zhang, J.A. Westberg, E. Hölttä, L.C. Andersson, Bcl-2 regulates neural
differentiation, Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 4504–4508.
[42] G. Raguenez, L. Desire, V. Lantrua, Y. Courtois, Bcl-2 is upregulated in
human SH-SY5Y neuroblastoma cells differentiated by overexpression of
fibroblast growth factor 1, Biochem. Biophys. Res. Commun. 258 (1999)
745–751.
[43] J.H. Myklebust, E.B. Smeland, D. Josefsen, M. Sioud, Protein kinase C-α
isoform is involved in erythropoietin-induced erythroid differentiation of
CD34+ progenitor cells from human bone marrow, Blood 95 (2000)
510–518.
[44] M. Csete, L. Rodriguez, M. Wilcox, S. Chadalavada, Erythropoietin
receptor is expressed on adult rat dopaminergic neurons and erythropoietin
is neurotrophic in cultured dopaminergic neuroblasts, Neurosci. Lett. 359
(2004) 124–126.
